Literature DB >> 32072917

Apoptotic Effects of Melittin on 4T1 Breast Cancer Cell Line is associated with Up Regulation of Mfn1 and Drp1 mRNA Expression.

Farnaz D Moghaddam1, Pejman Mortazavi2, Somayeh Hamedi3, Mohammad Nabiuni4, Nasim H Roodbari1.   

Abstract

BACKGROUND AND
PURPOSE: Melittin, as the main ingredient of honeybee venom, that has shown anticancer properties. The present study aimed at investigating the cytotoxic impacts of melittin on 4T1 breast cancer cells.
METHODS: Hemolytic activity of different concentrations (0.125, 0.25, 0.5, 1, 2, 4, 8μg/ml) of melittin was assayed and then cytotoxicity of selected concentrations of melittin (2, 4, 8, 16, 32, and 64μg/ml), 2 and 4μg/ml of cisplatin and 0.513, 0.295 and 0.123μg/ml of doxorubicin was evaluated on 4T1 cells using MTT assay. We used Morphological evaluation and flow cytometric analysis was used. Real time PCR was also used to determine mRNA expression of Mfn1 and Drp1 genes.
RESULTS: All compounds showed anti-proliferative effects on the tumor cell line with different potencies. Melittin had higher cytotoxicity against 4T1 breast cancer cells (IC50= 32μg/ml-72h) and higher hemolytic activity (HD50= 1μg/ml), as compared to cisplatin and doxorubicin. Mellitin at 16 and 32μg/ml showed apoptotic effects on 4T1 cells according to the flow cytometric analysis. The Real time PCR analysis of Drp1 and Mfn1 expression in cells treated with 16μg/ml of melittin revealed an up-regulation in Drp1 and Mfn1 genes mRNA expression in comparison with control group. Treatment with 32μg/ml of melittin was also associated with a rise in mRNA expression of Drp1 and Mfn1 as compared to the control group.
CONCLUSION: The results of this study showed that melittin has anticancer effects on 4T1 cell lines in a dose and time dependent manner and can be a good candidate for further research on breast cancer treatment. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  4T1; apoptosis; breast cancer; cisplatin; doxorubicin; melittin

Mesh:

Substances:

Year:  2020        PMID: 32072917     DOI: 10.2174/1871520620666200211091451

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  8 in total

Review 1.  Applications and evolution of melittin, the quintessential membrane active peptide.

Authors:  Shantanu Guha; Ryan P Ferrie; Jenisha Ghimire; Cristina R Ventura; Eric Wu; Leisheng Sun; Sarah Y Kim; Gregory R Wiedman; Kalina Hristova; Wimley C Wimley
Journal:  Biochem Pharmacol       Date:  2021-09-17       Impact factor: 6.100

Review 2.  Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.

Authors:  Peiying Shi; Shihui Xie; Jiali Yang; Yi Zhang; Shuo Han; Songkun Su; Hong Yao
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

3.  Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis.

Authors:  Mingyi Jing; Yi Cai; Jing Shi; Xufan Zhang; Baohua Zhu; Fan Yuan; Jie Zhang; Min Xiao; Mingling Chen
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 4.  Relevance of Membrane Contact Sites in Cancer Progression.

Authors:  Aurora Gil-Hernández; Miguel Arroyo-Campuzano; Arturo Simoni-Nieves; Cecilia Zazueta; Luis Enrique Gomez-Quiroz; Alejandro Silva-Palacios
Journal:  Front Cell Dev Biol       Date:  2021-01-12

Review 5.  Mesoporous Bioactive Glasses in Cancer Diagnosis and Therapy: Stimuli-Responsive, Toxicity, Immunogenicity, and Clinical Translation.

Authors:  Esmaeel Sharifi; Ashkan Bigham; Satar Yousefiasl; Maria Trovato; Matineh Ghomi; Yasaman Esmaeili; Pouria Samadi; Ali Zarrabi; Milad Ashrafizadeh; Shokrollah Sharifi; Rossella Sartorius; Farnaz Dabbagh Moghaddam; Aziz Maleki; Hao Song; Tarun Agarwal; Tapas Kumar Maiti; Nasser Nikfarjam; Colin Burvill; Virgilio Mattoli; Maria Grazia Raucci; Kai Zheng; Aldo R Boccaccini; Luigi Ambrosio; Pooyan Makvandi
Journal:  Adv Sci (Weinh)       Date:  2021-11-19       Impact factor: 16.806

6.  pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer.

Authors:  Ali Moammeri; Koorosh Abbaspour; Alireza Zafarian; Elham Jamshidifar; Hamidreza Motasadizadeh; Farnaz Dabbagh Moghaddam; Zeinab Salehi; Pooyan Makvandi; Rassoul Dinarvand
Journal:  ACS Appl Bio Mater       Date:  2022-02-07

Review 7.  Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges.

Authors:  Chaochao Yu; Yi Li; Guopeng Chen; Chaoyan Wu; Xiuping Wang; Yingwen Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2022-07-15       Impact factor: 5.552

8.  A new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin.

Authors:  Mackson Martins Rocha; Isabela Dariva; Gabriela Comelli Zornoff; Giovanna Sanches De Laurentis; Giulia Carli Mendes; Maycon Giovani Santana; Guilherme Chohfi de Miguel; Rui Seabra Ferreira; Juliana Mozer Sciani; Denise Gonçalves Priolli
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.